Alnylam Pharmaceuticals
ALNY
#527
Rank
$41.79 B
Marketcap
$320.53
Share price
-1.28%
Change (1 day)
34.77%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2025 (TTM): -$0.22 Billion USD

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are $2.34 Billion USD. In 2024 the company made an earning of -$0.24 Billion USD, an increase over its 2023 earnings that were of -$0.32 Billion USD. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -$0.22 Billion-10.78%
2024 -$0.24 Billion-24.59%
2023 -$0.32 Billion-67.84%
2022 -$0.98 Billion36.93%
2021 -$0.71 Billion-8.04%
2020 -$0.78 Billion-15.66%
2019 -$0.92 Billion12.23%
2018 -$0.82 Billion62.91%
2017 -$0.51 Billion17.78%
2016 -$0.43 Billion43.44%
2015 -$0.3 Billion60.69%
2014 -$0.19 Billion98.2%
2013 -$92.95 Million
2011 -$54.82 Million27.48%
2010 -$43.01 Million-10.92%
2009 -$48.28 Million95.77%
2008 -$24.66 Million
2006 -$39.51 Million-9.13%
2005 -$43.48 Million34.74%
2004 -$32.27 Million36.79%
2003 -$23.59 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Arrowhead Pharmaceuticals
ARWR
-$89.25 Million-57.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
$4.98 B-2,471.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-$0.17 Billion-21.86%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-$0.56 Million-99.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-$47.43 Million-77.43%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
$14.91 B-7,199.31%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
$8.76 B-4,273.11%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
$0.45 B-316.05%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel